For example, our use of immunoprecipitation to deplete serum of CD163 in our lymphocyte proliferation experiments leaves open the possibility that the difference in proliferation rates which we observed between lymphocytes treated with CD163-depleted and CD163-normal ischemic stroke serum was driven by the removal of an off-target molecule other than CD163 via a non-specific antibody interaction. The gene discussed is CD163; the disease is ischemic stroke.